Improving Pain Management and Opioid Safety for Patients with Cirrhosis
改善肝硬化患者的疼痛管理和阿片类药物的安全性
基本信息
- 批准号:10586061
- 负责人:
- 金额:$ 18.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2024-09-30
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAcetaminophenAddressAdverse eventAffectAlcohol consumptionAlcoholsAnalgesicsAwardBehaviorBehavior TherapyBehavioralBehavioral SciencesCessation of lifeChronic Kidney FailureCicatrixCirrhosisComplexCoupledDataDevelopmentDoseEvidence based interventionEvidence based treatmentExerciseFoundationsFutureGastroenterologistGeneral PopulationGoalsGuidelinesHelping to End Addiction Long-termHepatic EncephalopathyHepatitis CHepatitis C virusHospitalizationImpaired cognitionInterventionIntervention TrialInterviewLifeLiverLiver CirrhosisLiver diseasesMediatingMedicalMental HealthMental disordersMentored Clinical Scientist Development ProgramMentored Patient-Oriented Research Career Development AwardMentorsMentorshipNational Institute of Drug AbuseNon-Steroidal Anti-Inflammatory AgentsOpioidOpioid AnalgesicsOverdosePainPain MeasurementPain managementPatientsPersistent painPersonsPharmaceutical PreparationsPopulationPositioning AttributePublic HealthRandomizedRecommendationRelaxationResearchResearch PersonnelRiskScienceSiteStructureSubstance Use DisorderSymptomsTarget PopulationsTestingToxic effectTrainingTransplantationUnited StatesUnited States National Institutes of HealthWorkacceptability and feasibilitybehavioral clinical trialcareerchronic painchronic pain managementchronic pain patientcomorbiditydesignefficacy trialexperiencehigh riskhigh risk populationimprovedinnovationinterestintervention mappingliver transplantationmortalitymultidisciplinarynon-opioid analgesicopioid epidemicopioid misuseopioid mortalityopioid overdoseopioid overuseopioid therapyopioid useoverdose deathpain reliefpain self-managementpatient populationpatient safetypharmacologicpilot testpilot trialprescription opioidprimary outcomeskillssocial cognitive theorysubstance usesuccesstheoriestherapy designtreatment as usual
项目摘要
Prescription opioid medications are a leading cause of opioid-related death and are particularly risky in patients
with liver cirrhosis. Cirrhosis affects four million people in the US and is most often due to alcohol or substance
use disorder (SUD)-mediated hepatitis C. In this population, prescription opioids are associated with decreased
access to life-saving transplantation and increased complications of liver disease, hospitalizations, and
mortality. Despite these risks, approximately half of all patients with cirrhosis are prescribed opioid medications
each year. This is likely because 80% of patients with cirrhosis have chronic pain and alternative pain
management strategies have not been designed for or tested in this population. Indeed, existing pain
management interventions designed for general populations do not address many of the specific issues facing
patients with cirrhosis such as their overall high symptom burden, contraindications to most common analgesic
medications, and underlying mental health and SUDs. The National Pain Strategy recommends using
behavioral interventions, specifically pain self-management interventions, to address chronic pain. However,
such interventions are most effective when they are designed to address the specific needs of the population
of interest. Therefore, the overarching research goal of this K23 award is to develop and test a behavioral
intervention for chronic pain for patients with cirrhosis. This goal will be achieved through the following Specific
Aims: Aim 1) To develop a theory-based behavioral intervention to improve pain and function for patients with
cirrhosis; and Aim 2) To conduct a randomized pilot trial of the intervention developed in Aim 1. Existing pain
self-management interventions will serve as a starting point for this work. Following the established steps of
Intervention Mapping (IM), a structured approach to developing theory-based behavioral interventions,
stakeholder input and semi-structured interviews will be integrated into a behavioral intervention for pain that
addresses the needs of patients with cirrhosis. The resulting intervention will be pilot tested in 40 patients with
cirrhosis and chronic pain. This research is significant because it aims to address the national opioid crisis in a
high-risk, understudied population. Furthermore, this approach may be applicable to other populations with
high rates of chronic pain and SUDs. This research is innovative because it will lead to the first intervention for
pain for this population. Dr. Shari Rogal is uniquely positioned to conduct this study, as she is a
gastroenterologist and transplant hepatologist with a research focus on studies of SUDs and pain in the
context of liver disease. Through this award Dr. Rogal will receive additional training in chronic pain science,
behavioral science, and behavioral clinical trials, as well as the support of a multidisciplinary mentoring team.
This K23 will thus allow her to develop an independent research career as a leader in developing, testing, and
implementing interventions for chronic pain in patients with complex medical, mental health, and substance
use comorbidities.
处方阿片类药物是阿片类药物相关死亡的主要原因,对患者来说尤其危险
患有肝硬化。肝硬化影响美国四百万人,最常见的原因是酒精或药物
使用障碍 (SUD) 介导的丙型肝炎。在该人群中,处方阿片类药物与丙型肝炎的减少有关
获得挽救生命的移植以及肝病、住院和住院的并发症增加
死亡。尽管存在这些风险,大约一半的肝硬化患者仍服用阿片类药物
每年。这可能是因为 80% 的肝硬化患者有慢性疼痛和替代性疼痛
尚未针对这一人群设计或测试管理策略。确实,现有的痛苦
为一般人群设计的管理干预措施并不能解决面临的许多具体问题
肝硬化患者,例如总体症状负担较高、最常见镇痛药的禁忌症
药物、潜在的心理健康和 SUD。国家疼痛战略建议使用
行为干预,特别是疼痛自我管理干预,以解决慢性疼痛。然而,
此类干预措施在旨在满足民众的具体需求时最为有效
的兴趣。因此,K23 奖项的总体研究目标是开发和测试行为
肝硬化患者慢性疼痛的干预。这一目标将通过以下具体措施来实现
目的: 目标 1) 开发一种基于理论的行为干预措施,以改善患有以下疾病的患者的疼痛和功能:
肝硬化;目标 2) 对目标 1 中开发的干预措施进行随机试点试验。现有疼痛
自我管理干预措施将作为这项工作的起点。按照既定步骤
干预映射(IM),一种开发基于理论的行为干预的结构化方法,
利益相关者的意见和半结构化访谈将被纳入针对疼痛的行为干预中,
满足肝硬化患者的需求。由此产生的干预措施将在 40 名患有以下疾病的患者中进行试点测试
肝硬化和慢性疼痛。这项研究意义重大,因为它旨在解决国家阿片类药物危机
高风险、未充分研究的人群。此外,这种方法可能适用于其他人群
慢性疼痛和 SUD 的发病率很高。这项研究具有创新性,因为它将导致首次干预
这群人的痛苦。 Shari Rogal 博士具有独特的优势来开展这项研究,因为她是一名
胃肠病学家和移植肝病学家,研究重点是 SUD 和疼痛的研究
肝脏疾病的背景。通过该奖项,罗加尔博士将接受慢性疼痛科学方面的额外培训,
行为科学和行为临床试验,以及多学科指导团队的支持。
因此,这个 K23 将使她能够作为开发、测试和应用领域的领导者发展独立的研究生涯。
对患有复杂医疗、心理健康和物质的患者实施慢性疼痛干预措施
使用合并症。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Organizational and Implementation Factors Associated with Cirrhosis Care in the Veterans Health Administration.
退伍军人健康管理局中与肝硬化护理相关的组织和实施因素。
- DOI:
- 发表时间:2024-04-14
- 期刊:
- 影响因子:3.1
- 作者:McCurdy, Heather;Nobbe, Anna;Scott, Dawn;Patton, Heather;Morgan, Timothy R;Bajaj, Jasmohan S;Yakovchenko, Vera;Merante, Monica;Gibson, Sandra;Lamorte, Carolyn;Baffy, Gyorgy;Ioannou, George N;Taddei, Tamar H;Rozenberg;Anwar
- 通讯作者:Anwar
AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis.
AASLD 实践指南:失代偿性肝硬化的姑息治疗和基于症状的管理。
- DOI:
- 发表时间:2022-09
- 期刊:
- 影响因子:0
- 作者:Rogal, Shari S;Hansen, Lissi;Patel, Arpan;Ufere, Nneka N;Verma, Manisha;Woodrell, Christopher D;Kanwal, Fasiha
- 通讯作者:Kanwal, Fasiha
Alcohol treatment discussions and clinical outcomes among patients with alcohol-related cirrhosis.
酒精相关性肝硬化患者的酒精治疗讨论和临床结果。
- DOI:
- 发表时间:2023-02-02
- 期刊:
- 影响因子:2.4
- 作者:Alexandre, Wheytnie;Muhammad, Haseeb;Agbalajobi, Olufunso;Zhang, Grace;Gmelin, Theresa;Adejumo, Adeyinka;Noll, Alan;Jonassaint, Naudia L;DiMartini, Andrea;Bataller, Ramon;Rogal, Shari S
- 通讯作者:Rogal, Shari S
Getting to implementation: Adaptation of an implementation playbook.
实施:改编实施手册。
- DOI:
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Yakovchenko, Vera;Rogal, Shari S;Goodrich, David E;Lamorte, Carolyn;Neely, Brittney;Merante, Monica;Gibson, Sandra;Scott, Dawn;McCurdy, Heather;Nobbe, Anna;Morgan, Timothy R;Chinman, Matthew J
- 通讯作者:Chinman, Matthew J
Refining Expert Recommendations for Implementing Change (ERIC) strategy surveys using cognitive interviews with frontline providers.
通过对一线提供者进行认知访谈,完善实施变革的专家建议 (ERIC) 策略调查。
- DOI:
- 发表时间:2023-04-21
- 期刊:
- 影响因子:0
- 作者:Yakovchenko, Vera;Chinman, Matthew J;Lamorte, Carolyn;Powell, Byron J;Waltz, Thomas J;Merante, Monica;Gibson, Sandra;Neely, Brittney;Morgan, Timothy R;Rogal, Shari S
- 通讯作者:Rogal, Shari S
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shari S Rogal其他文献
Shari S Rogal的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shari S Rogal', 18)}}的其他基金
Improving Pain Management and Opioid Safety for Patients with Cirrhosis
改善肝硬化患者的疼痛管理和阿片类药物的安全性
- 批准号:
10399413 - 财政年份:2020
- 资助金额:
$ 18.87万 - 项目类别:
Improving Pain Management and Opioid Safety for Patients with Cirrhosis
改善肝硬化患者的疼痛管理和阿片类药物的安全性
- 批准号:
9891598 - 财政年份:2020
- 资助金额:
$ 18.87万 - 项目类别:
Using Data-Driven Implementation Strategies to Improve the Quality of Cirrhosis Care
使用数据驱动的实施策略提高肝硬化护理质量
- 批准号:
10178108 - 财政年份:2019
- 资助金额:
$ 18.87万 - 项目类别:
相似国自然基金
CHAC1通过调控蛋白谷胱甘肽化修饰促进对乙酰氨基酚诱导急性药物性肝损伤的作用和机制研究
- 批准号:82370597
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
金银花中绿原酸类化合物通过激活Keap1/Nrf2-PPARα通路促进对乙酰氨基酚肝损伤后肝脏再生修复的研究
- 批准号:82304845
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于超小MOF-818构筑的纳米酶复合物催化前药对乙酰氨基酚的氧化及其抗肿瘤机制
- 批准号:32371463
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
IER2通过Hippo信号通路保护对乙酰氨基酚诱导的肝损伤
- 批准号:82373967
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
ENDOG促进对乙酰氨基酚引起肝损伤的作用及机制研究
- 批准号:82370596
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Ataxia Telangiectasia Mutated (ATM)-mediated hepatic DNA damage in pediatric nonalcoholic fatty liver disease
共济失调毛细血管扩张突变 (ATM) 介导的儿童非酒精性脂肪性肝病中的肝 DNA 损伤
- 批准号:
10674036 - 财政年份:2021
- 资助金额:
$ 18.87万 - 项目类别:
Sexual dimorphism of acetaminophen-induced liver injury and regeneration
对乙酰氨基酚诱导的肝损伤和再生的性别二态性
- 批准号:
10440279 - 财政年份:2021
- 资助金额:
$ 18.87万 - 项目类别:
Sexual dimorphism of acetaminophen-induced liver injury and regeneration
对乙酰氨基酚诱导的肝损伤和再生的性别二态性
- 批准号:
10315150 - 财政年份:2021
- 资助金额:
$ 18.87万 - 项目类别:
Multiplexed Nucleation Approaches for Enhanced High Throughput Screening of Co-Crystals
用于增强共晶高通量筛选的多重成核方法
- 批准号:
10081479 - 财政年份:2016
- 资助金额:
$ 18.87万 - 项目类别:
Multiplexed Nucleation Approaches for Enhanced High Throughput Screening of Co-Crystals
用于增强共晶高通量筛选的多重成核方法
- 批准号:
10226342 - 财政年份:2016
- 资助金额:
$ 18.87万 - 项目类别: